RET-antilichaam [64C4]

RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cell-surface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.

5979

P07949

P07949

Human

6E4C4

Unconjugated

Primary Antibodies

Signal Transduction

Batch dependent

Ascitic fluid containing 0.03% sodium azide.

None

Blue Ice

RET monoclonal antibody can be stored at -20˚ C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

IgG1

RET

Ret proto-oncogene

Homo sapiens

Young HM. Anderson RB. Anderson CR. Auton Neurosci. 2004, May 31,112 (1-2) :1-14.

Myers SM. Mulligan LM. Cancer Res. 2004, Jul 1,64 (13) :4453-63.

CDHF12, CDHR16, PTC, RET51, Cadherin family member 12PTC, MTC1, HSCR1, MEN2A, MEN2B, CDHF12, RET-ELE1

ELISA, WB

547807